Kodiak Sciences Inc.
KODHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeKodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. With a market capitalization of $2.22B, it sits in mid-cap territory. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Market Cap
$2.22B
Beta
2.18
P/E (TTM)
—
P/E (Fwd)
-9.44
EPS (TTM)
$-4.19
EPS (Fwd)
$-3.75
ROE
-368.4%
ROA
-60.5%
Cash
$125.9M
Total Debt
$52.8M
Free CF
-$58.4M
52W Change
251.5%
Annual Financials
Cash vs Debt
Where KOD stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, KOD finished 4.36% above its 150-day moving average ($35.51) and 12.71% above its 200-day moving average ($32.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KOD overbought or oversold?
At the September 2, 2026 close, KOD's RSI(14) was 26.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $125.9M in cash and $52.8M in debt, KOD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$58.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -368.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, KOD tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kodiak Sciences Inc.'s trajectory.